Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab

Ashley Hopkins, Ganessan Kichenadasse, Elizabeth Garrett-Meyer, Christos Karapetis, Andrew Rowland, Michael J Sorich

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PURPOSE: Immune checkpoint inhibitors (ICI) are a significant advance to the treatment of advanced non-small cell lung cancer (NSCLC); however, their initiation is associated with heterogeneity in outcomes. This study aimed to develop and validate a prognostic tool of survival in patients with advanced NSCLC treated with ICIs. EXPERIMENTAL DESIGN: A pretreatment prognostic model was developed and validated using clinicopathologic data. Development data consisted of patients with advanced NSCLC treated with atezolizumab from the randomised trials OAK and POPLAR (n = 751). Data from the single-arm atezolizumab trials BIRCH and FIR (n = 797) were used for external validation. Prognostic scores were categorized into low, intermediate-low, intermediate, intermediate-high, and high-risk prognostic groups. The primary outcome was overall survival (OS), with progression-free survival (PFS) secondary. RESULTS: Pretreatment C-reactive protein (CRP) was the most predictive variable for OS. The prognostic tool was optimally defined by CRP, lactate dehydrogenase, derived neutrophil-to-lymphocyte ratio, albumin, PD-L1 expression, performance status, time since metastatic diagnosis, and metastatic site count. Prognostic groups had significantly different OS (c-statistic = 0.72), with median OS ranging from >24 to 3 months for the low- to high-risk groups. Performance was maintained on validation (c = 0.76). These findings were similar for PFS, with median PFS ranging from 5 months to 1 month for the low- to high-risk groups. Benefit of atezolizumab (vs. docetaxel) was greatest in the low-risk group (>3 months median OS improvement), with little benefit apparent for the highest risk group. CONCLUSIONS: A prognostic tool was developed and validated to identify patient groups with distinctly different survival following atezolizumab initiation for advanced NSCLC.

Original languageEnglish
Pages (from-to)3280-3286
Number of pages7
JournalClinical Cancer Research
Volume26
Issue number13
Early online date21 Feb 2020
DOIs
Publication statusPublished - Jul 2020

Keywords

  • Immune checkpoint inhibitors (ICI)
  • non-small cell lung cancer (NSCLC
  • prognostic model

Fingerprint Dive into the research topics of 'Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab'. Together they form a unique fingerprint.

  • Cite this